Showing results (41-50 of 343) with videos related to
Sort By:
Pageof 35
Expert Opinion on Biological Therapy|October 22, 2002
Antitumour necrosis factor therapy in Crohn's diseaseHerbert Tilg, Arthur KaserExpert Opinion on Biological Therapy|April 23, 2004
Type I interferons and their therapeutic role in Th2-regulated inflammatory disordersHerbert Tilg, Arthur KaserThe Journal of Clinical Investigation|June 3, 2011
Gut microbiome, obesity, and metabolic dysfunctionHerbert Tilg, Arthur KaserMetabolism: Clinical and Experimental|February 25, 2016
Nonalcoholic fatty liver disease and hepatocellular carcinomaHeinz Zoller, Herbert TilgCurrent Opinion in Clinical Nutrition and Metabolic Care|May 18, 2010
Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammationHerbert Tilg, Alexander MoschenCurrent Opinion in Investigational Drugs (London, England : 2000)|December 16, 2010
Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's diseaseHerbert Tilg, Arthur KaserExpert Opinion on Therapeutic Targets|February 25, 2009
Inflammatory bowel diseases: highlights from the United European Gastroenterology Week 2008Arthur Kaser, Herbert TilgNature Clinical Practice. Gastroenterology & Hepatology|November 3, 2005
Treatment strategies in nonalcoholic fatty liver diseaseHerbert Tilg, Arthur KaserCurrent Drug Delivery|October 26, 2011
"Metabolic aspects" in inflammatory bowel diseasesArthur Kaser, Herbert TilgEuropean Journal of Gastroenterology & Hepatology|November 20, 2002
Splanchnic blood flow determination in patients with suspected chronic intestinal ischaemiaHerbert Tilg, Hannes GaenzerPageof 35